Risk Level: LowSubQ Inject

AOD-9604

Targeted Adipocyte Lipolysis & Zero Glycemic/Insulin Disturbance

Aliases / Trademarks: Advanced Obesity Drug-9604 · hGH Fragment 177-191 Variant

A modified C-terminal fragment of human Growth Hormone (hGH 177-191). Preserves hGH's potent lipolytic fat-breakdown capacity while completely eliminating effects on blood glucose, insulin resistance, or acromegaly.

🧬 Synergy Blueprint

Associated Protocol Category: View Protocol Roadmap

📊 Reddit & Community Real-World Scorecard390 Aggregated Logs

90% Overall Satisfaction

Onset Speed Perception

4.1 / 5.0

Noticeable within 1-2 weeks

Injection Pain / PIP

1.0 / 5.0

SubQ injection virtually painless

Cost-to-Value Index

4.3 / 5.0

Premium therapeutic cost (~$80-$150/mo)

⏱️ Real-World Expectation & Sentiment Timeline

Click stages below to view milestone milestones & warnings

Week 1 - 4：Adipocyte Mobilization Phase Core Milestones

Increased sweat response during morning fasted cardio; stubborn localized fat deposits feel softer and less dense

Stage Critical Guidance:Inject first thing in the morning in a strict fasted state, immediately followed by 30 minutes of Zone 2 cardio.

Standard Dosage & Administration Guidelines

Typical Dose

300mcg - 500mcg / day

Frequency

Daily morning SubQ injection in a fasted state

Cycle Length

6 - 8 weeks on, followed by 4 weeks off

Clinical & Community Notes: Administering upon waking in a fasted state followed immediately by low-intensity steady-state cardio (Zone 2) doubles the rate of mobilized fatty acid oxidation.

Titration Schedule & Dosing Decision Tree

Step-up Protocol

Starting & Maintenance Criteria:300mcg SubQ upon waking in a fasted state

Maintain 300mcg - 500mcg daily for 6-8 weeks

Titration & Adjustment Rules:If well tolerated, advance to 500mcg daily

Timeline	Dosage & Frequency	Objective	Key Biomarkers / Checks
Weeks 1 - 8	300mcg - 500mcg daily (fasted morning SubQ)	Targeted lipolysis of stubborn subcutaneous fat depots	Skinfold caliper thickness, waist measurement

Educational Composite Scenarios

1 Composite Archetypes

ℹ️ Names, timelines, doses, lab values, and outcomes are illustrative composites. They are not actual patient records or treatment recommendations.

8-Week AOD-9604 Protocol: Stubborn Android Fat Loss with Zero Glycemic Impact

👤 Composite Profile: Female, 33yo, fitness instructor, postpartum 2 years with lean overall physique (21% BF) but localized stubborn android fat (24mm skinfold); highly intolerant to GLP-1 GI side effects.

Illustrative Protocol: AOD-9604 500mcg SubQ daily into lower abdomen, administered in a strict fasted state followed by 45 min fast and 30 min Zone 2 aerobic cardio, 5 days/week.

Illustrative Timeline:

Week 1Skinfold 24mm -> 22mm

Fasted SubQ injection was pain-free; zero jitters, palpitations, or nausea observed.

Week 4Skinfold 22mm -> 16mm

Noticeable tightening across the lower abdomen; stubborn adipose matrix became softer and thinner.

Week 8Skinfold Settled at 12mm

Six-pack abdominal contours fully emerged; lab recheck scenario observation indicated zero disruption to glucose homeostasis.

Scenario Outcome and Learning Points: Successfully eliminated 50% of localized stubborn android fat with zero appetite blunting, zero muscle catabolism, and perfect glycemic stability.

💡 Educational Takeaway: AOD-9604 represents the C-terminal lipolytic domain of hGH (177-191) with zero IGF-1 elevating or diabetogenic properties. Strictly administer in a fasted low-insulin state to unlock beta-oxidation.

Visual Syringe Reconstitution Calculator

Accurately calculate vial reconstitution concentration and U-100 syringe units

Syringe:

Quick Clinical & Community Presets:

① Vial Mass (Powder Quantity)5 mg

② BAC Water Added2 ml

③ Target Desired Dose

mcg

Syringe Pull To Mark

12Units (Ticks on Syringe)

Equal to 0.120 ml fluid | Yields 16.7 doses

Conc: 2.50 mg/ml

💉 Visual Needle Simulation (U-100 Standard)Target: 12 / 100 U

① Dissolution Technique: Slowly slide BAC water down the vial wall. Never shake vigorously to protect peptide chains.

② Cold-Chain Storage: Store reconstituted liquid at 2-8°C away from light. Best used within 28-30 days.

③ Standard Syringe: Calculation based on U-100 insulin syringes (100 units = 1.0 ml).

Evidence-Based FAQs & Reddit Theoretical Mythbusters

Verified biochemical mechanisms, category physiology, and Reddit misconception clarity

1 Verified Answers

1. Compound-Specific Dilemmas & Solutions

No! AOD-9604 contains exclusively the lipolytic domain and lacks the receptor binding domains responsible for IGF-1 release and hepatic glucose output, showing zero impact on fasting glucose in human trials.

🔗 Synergistic Stacking Protocols (Synergies)

Synergy Stack

+ Tirzepatide

Tirzepatide suppresses appetite and clears visceral fat, while AOD-9604 mobilizes stubborn subcutaneous adipose.

View Tirzepatide Inspect Stacking Graph

📊 Educational Composite Scenarios (1)

Illustrative 6-16 week timelines, sample biomarker metrics, and educational protocol takeaways for AOD-9604.

View All Scenarios Hub →

ℹ️ Names, timelines, doses, lab values, and outcomes are illustrative composites. They are not actual patient records or treatment recommendations.

Textbook ResponderFemale, 33 y/o•8 Weeks Protocol

8-Week AOD-9604 Protocol: Stubborn Android Fat Loss with Zero Glycemic Impact

Illustrative Protocol: AOD-9604 500mcg SubQ daily into lower abdomen, administered in a strict fasted state followed by 45 min fast and 30 min Zone 2 aerobic cardio, 5 days/week.

Lower Ab Skinfold

12 mm

-50% (Visible Abdominal Definition)

Trunk Fat Loss

-2.6 kg

Targeted Android Lipolysis

Lean Muscle Mass

(0kg Loss)

100% Muscle Retention

Illustrative Weekly Highlights:

Week 1Fasted SubQ injection was pain-free; zero jitters, palpitations, or nausea observed.

Week 4Noticeable tightening across the lower abdomen; stubborn adipose matrix became softer and thinner.

Week 8Six-pack abdominal contours fully emerged; lab recheck scenario observation indicated zero disruption to glucose homeostasis.

Inspect Full Scenario Dossier →

Dedicated Dose & Syringe Calculator

💉 AOD-9604 Reconstitution & Syringe Tick Tool

Standard vial size: 5mg. Recommended BAC water: 2ml. Typical dose: 300mcg - 500mcg / day.

Visual Syringe Reconstitution Calculator

Accurately calculate vial reconstitution concentration and U-100 syringe units

Syringe:

Quick Clinical & Community Presets:

① Vial Mass (Powder Quantity)5 mg

② BAC Water Added2 ml

③ Target Desired Dose

mcg

Syringe Pull To Mark

10Units (Ticks on Syringe)

Equal to 0.100 ml fluid | Yields 20 doses

Conc: 2.50 mg/ml

💉 Visual Needle Simulation (U-100 Standard)Target: 10 / 100 U

① Dissolution Technique: Slowly slide BAC water down the vial wall. Never shake vigorously to protect peptide chains.

② Cold-Chain Storage: Store reconstituted liquid at 2-8°C away from light. Best used within 28-30 days.

③ Standard Syringe: Calculation based on U-100 insulin syringes (100 units = 1.0 ml).

Evidence Context and Common Questions

AOD-9604 Key Takeaways

Evidence Context and Common Questions

300mcg - 500mcg / day, administered Daily morning SubQ injection in a fasted state for a cycle length of 6 - 8 weeks on, followed by 4 weeks off. Consensus: Administering upon waking in a fasted state followed immediately by low-intensity steady-state cardio (Zone 2) doubles the rate of mobilized fatty acid oxidation.

Back to Peptides Directory

Research References

References may include preclinical or clinical research and do not establish safety, efficacy, or dosing for an individual.

The effects of AOD9604 on body weight and lipid metabolism in obese subjects

International Journal of Obesity · 2004

Open DOI: 10.1038/sj.ijo.0802640